Back to search

France· FR:66266368

RIZMOIC 200 microgrammes, comprimé pelliculé

A naldemedine product containing tosylate de naldémédine, registered in France by SHIONOGI (PAYS BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC A06AH05

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedRIZMOIC 200 microgrammes, comprimé pe…ATCA06AH05REGISTER NO.FR:66266368PACKS LISTED2CHECKEDSeptember 12, 2026

Where it is registered

Naldemedine is registered in 14 of 19 countries.

Countries holding a registration under ATC A06AH05 (naldemedine), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Naldemedine · ATC A06AH05

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of naldemedine costs, country by country.

Normalised to the WHO defined daily dose (0.2 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Naldemedine · price per daily dose (0.2 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.82
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TOSYLATE DE NALDÉMÉDINE
Manufacturer
SHIONOGI (PAYS BAS)
Country
France (FR)
ATC code
A06AH05
ATC class
Naldemedine
Defined daily dose
0.2 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

2 priced
  • cip13
    3400930278406
    plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
    EUR 50.26
  • cip13
    3400930323175
    30 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 1 comprimé(s)
    EUR 50.26

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

174 interactions on record for naldemedine.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Naldemedine · interactions on record

174 records

  • 12 severe
  • 160 moderate
  • 2 minor

Most severe, free to view

  • RifampicinJ04AB02severe
  • RifapentineJ04AB05severe
  • MitotaneL01XX23severe
  • EnzalutamideL02BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Naldemedine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naldemedine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rizmoic
  • Liechtenstein · Rizmoic
  • Norway · Rizmoic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c60b899c-b5ac-4a2d-b8c0-b6edf5d27dba
GET /v1/drugs/c60b899c-b5ac-4a2d-b8c0-b6edf5d27dba?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66266368",
  "date_amm": "2019-02-18",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/18/1291",
  "substance": "TOSYLATE DE NALDÉMÉDINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about naldemedine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.